Does creatine reduce inflammation? What the 2026 evidence actually shows

A new pair of research syntheses gives creatine marketers a cleaner split than they might like. In a 2026 meta-analysis published in Frontiers in Nutrition, Yu Zhang and colleagues found that creatine supplementation improved anaerobic power and lean mass, especially when paired with resistance training. Separately, a 2026 systematic review and meta-analysis in Frontiers in Immunology led by Kell Mazzini Ribeiro de Camargo found no consistent reduction in the two inflammatory markers everyone checks first: C-reactive protein and interleukin-6. For readers who have been sold creatine as both a gym-performance staple and a recovery shortcut, the new evidence points in only one of those directions.

The anti-inflammatory claim has drifted far beyond the data, and the gap is worth looking at. Creatine does have a plausible biological story. It can alter cellular energy handling, may affect oxidative stress, and has been discussed for years as a possible recovery aid. But plausibility is not the same thing as a measurable change in people. Pulling back from the marketing, the new papers suggest the most defensible reason to take creatine is still the old one: it helps training output and body-composition outcomes more reliably than it quiets systemic inflammation.

What the 2026 studies actually showed

Zhang and colleagues pooled 39 randomized controlled trials in young men, separating studies that combined creatine with resistance training from those that did not. The performance signal was hard to miss. Across those trials, creatine was associated with gains in Wingate peak power, Wingate mean power, fat-free mass, and lean body mass, with pooled differences of +71.27 W, +39.69 W, +3.39 kg, and +2.70 kg respectively. Those are not trivial numbers. They fit the part of creatine research that has held up best for years — short-burst performance and training-linked body-composition gains.

Even that paper stops short of being a blank cheque for every creatine promise, however. The strongest outcomes clustered around people who were already lifting, a useful corrective to the broader wellness pitch that often presents creatine as a kind of all-purpose vitality powder. The evidence here looked more specific than that. Creatine appears to work best when there is an actual training stimulus for it to amplify.

On the inflammation side, the paper was narrower and less flattering to the recovery narrative. Camargo and colleagues examined eight randomized double-blind placebo trials and focused on two familiar blood markers: CRP and IL-6. The pooled chronic effect on CRP came to -0.41 mg/L. For IL-6, the pooled chronic effect was -0.02 pg/mL. Those are small shifts, and the paper’s senior author Vitor E. Valenti told MedicalXpress that “the magnitude of the difference was small.” That sentence does more work than the headline. A statistically interesting effect is not automatically a clinically meaningful one, especially when the dataset is small.

CRP and IL-6 are blunt instruments. They can tell researchers something about systemic inflammation, but they do not map neatly onto every athlete’s day-after soreness or tissue-level recovery. Turning a non-result on those markers into a sweeping verdict about how creatine feels in the gym would be a mistake.

Why the inflammation claim keeps outrunning the evidence

Inflammation makes an appealing story to tell about supplements. It sounds modern, precise, and connected to recovery. Exercise physiology is not that simple, though. A temporary rise in inflammatory signalling after hard training is not automatically a problem to be suppressed — some of it is part of the adaptation process. Even if creatine had produced a clearer drop in CRP or IL-6, the next question would still have been whether blunting that response was helpful, neutral, or counterproductive.

Earlier literature already hinted that this space was messy. A 2022 systematic review and meta-analysis in Sports Medicine described a paradoxical pattern in muscle-damage markers rather than a clean recovery benefit. Separately, a 2022 review in Nutrients laid out several anti-inflammatory and anti-catabolic mechanisms that could make creatine look promising on paper. Mechanisms matter. But this is exactly where supplement coverage tends to slip: a mechanism can explain why a result might happen — it cannot stand in for the result happening consistently in humans.

The gap between mechanistic appeal and real-world effect is common in sports nutrition. Creatine is one of the better-evidenced supplements on the market, which may be why it so frequently gets overextended into claims it has not earned. Once a supplement clearly helps in one domain, marketers start treating adjacent benefits as if they were merely undiscovered rather than unproven. The 2026 inflammation review is a reminder that those are two different things.

Performance is still the main event

None of this means the case for creatine has weakened overall. The new papers reinforce a more sober version of the existing consensus: creatine still looks useful for high-intensity performance, lean-mass accrual, and resistance-training outcomes. That broader case extends beyond young male lifters, too. A 2025 meta-analysis of resistance-trained older adults indexed on PubMed found gains in muscular strength and lean tissue mass when creatine was paired with training — a result that fits the longer-running pattern in the literature.

The important shift is not whether creatine “works.” It is what, exactly, it works for. On current evidence, the strongest answer is performance support, not systemic inflammation control. Readers looking at creatine through a recovery lens should be careful not to confuse three different standards: feeling less sore after a workout, watching a lifestyle influencer talk about lower inflammation, and actually shifting validated biomarkers in repeated clinical trials.

This distinction matters on a practical level, too. A supplement that improves training capacity can still be worthwhile even if it does nothing special for inflammation. More repetitions at a given load. A little more peak power. A slightly larger lean-mass response over weeks of training. For some athletes, that alone may be enough to justify creatine. What the new evidence does not support is turning a performance supplement into an anti-inflammatory catch-all.

What this means for the creatine conversation

Vitalspell has covered creatine before — cognition, kidney-safety anxieties, ageing. This new paper cluster belongs in the same file because it clarifies a familiar pattern in supplement science: the oldest, most replicated benefit is usually the one that survives scrutiny. The newer, more fashionable claim tends to rest on thinner ground. For creatine, that durable core is still exercise performance.

Readers should process supplement headlines with that pattern in mind. When a fresh study says a product helps performance but not inflammation, the second half of that sentence is usually the more important one. It tells readers where not to overread the evidence. The newest research does not make creatine less credible. It makes the marketing around it easier to trim back to size.

References

1. de Camargo KMR, et al. Impact of creatine supplementation on inflammation: evidence from a systematic review and meta-analysis of randomized double-blind placebo trials. Frontiers in Immunology. 2026. Source
2. Zhang Y, et al. Creatine supplementation in young men under resistance versus non-resistance training: a systematic review and meta-analysis of strength, performance, and lean mass. Frontiers in Nutrition. 2026. Source
3. The paradoxical effect of creatine monohydrate on muscle damage markers: a systematic review and meta-analysis. Sports Medicine. 2022. Source
4. Anti-inflammatory and anti-catabolic effects of creatine supplementation: a brief review. Nutrients. 2022. Source
5. The impact of creatine supplementation associated with resistance training on muscular strength and lean tissue mass in the aged: a systematic review and meta-analysis. European Review of Aging and Physical Activity. 2025. Source